Biotechnology - Antibody & Protein Discovery Platforms
Strategic Profile
OmniAb's Biological Intelligence platform powers transgenic animal immune systems to create optimized antibody candidates, including proprietary technologies like OmniRat, OmniChicken, OmniMouse, and the newly launched OmniUltra platform. The company operates with 104 active partners, 399 active programs and 32 programs in clinical development or commercialization.
Cyborg Score Rationale
Strong adoption of AI-enabled platforms and expanded partner base enhance recurring, high-margin revenues while diversifying risk. Growth in late-stage partnered assets and cost reductions position the company for improved margins and accelerated path to profitability. However, losses remain substantial with cash runway concerns.
Top Insights
OmniUltra launched December 2025 - transgenic chicken generating human immune repertoires with ultralong CDRH3 domains enabling antibodies and peptide therapeutics for bispecifics, CAR-T, and radioligands.
Q3 2025 revenue $2.2M YoY decline with 9-month revenue $10.3M and $50.6M operating loss, indicating challenging near-term economics.
Company ended September 2025 with $59.5M cash after $30M August fundraising; 2025 guidance projects $18-22M revenue and year-end cash $52-56M.
Analyst consensus is "Strong Buy" with 12-month price target of $6.67, representing 271% upside from current $1.71 stock price.